Weiss Multi-Strategy Advisers’s Avadel Pharmaceuticals AVDL Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-26,000	Closed	-$317K	–	469
2015 Q4	$317K	Sell	26,000 -14,000	-35%	-$218K	0.02%	328
2015 Q3	$652K	Sell	40,000 -45,000	-53%	-$991K	0.03%	299
2015 Q2	$1.8M	Sell	85,000 -44,800	-35%	-$803K	0.07%	262
2015 Q1	$2.33M	Sell	129,800 -140,200	-52%	-$2.2M	0.1%	225
2014 Q4	$4.63M	Sell	270,000 -30,000	-10%	-$428K	0.16%	132
2014 Q3	$4.29M	Sell	300,000 -5,000	-2%	-$71.9K	0.1%	215
2014 Q2	$4.58M	Buy	305,000 +15,000	+5%	+$181K	0.1%	224
2014 Q1	$3.89M	Buy	+290,000	New	+$3.11M	0.08%	259

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

FPC

Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Weiss Multi-Strategy Advisers's AVDL Position: Q1 2016 in Review

Weiss Multi-Strategy Advisers sold out of Avadel Pharmaceuticals (AVDL) in Q1 2016, closing a stake of 26,000 shares — an estimated $317K sold.

Weiss Multi-Strategy Advisers first reported a position in AVDL in Q1 2014 and held it in 8 quarters. The position peaked at $4.63M in Q4 2014. 81 funds tracked by Wall St. Rank hold AVDL as of Q1 2016.

Weiss Multi-Strategy Advisers reported no remaining Avadel Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 26,000 Avadel Pharmaceuticals shares in Q1 2016, an estimated $317K.
Weiss Multi-Strategy Advisers first reported a position in Avadel Pharmaceuticals in Q1 2014 and held it in 8 quarters.
Weiss Multi-Strategy Advisers's Avadel Pharmaceuticals position peaked at $4.63M in Q4 2014.
81 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2016.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2016, filed 16 May 2016.